News | Heart Valve Technology | July 21, 2015

GlobalData Analyst: Edwards Lifesciences, Medtronic Devices to Redefine TAVR Space

Report notes Sapien 3, CoreValve Evolut R have corrected critical flaws of early models, demonstrate growing acceptance of TAVR

GlobalData, TAVR, Edwards, Medtronic, CoreValve Evolut R, Sapien 3

Sapien 3 image courtesy of Edwards Lifesciences

July 21, 2015 — The recent U.S. Food and Drug Administration (FDA) approvals of two next-generation transcatheter aortic valve replacements (TAVR) devices will transform the U.S. market for TAVR procedures over the next decade, according to an analyst with research and consulting firm GlobalData.

According to Premdharan Meyyan, GlobalData's analyst covering medical devices, Edwards Lifesciences' Sapien 3 and Medtronic's CoreValve Evolut R have corrected some of the critical flaws inherent in earlier models, namely the Sapien XT and CoreValve. As a result, these devices have reduced mortality and complication rates in patients with severe aortic stenosis.

Meyyan said:"The FDA's Sapien 3 approval is expected to solidify Edwards Lifesciences' TAVR market lead. The company has improved upon Sapien XT's design by incorporating a polyethylene terephthalate skirt into its product, which minimizes the incidence of paravalvular regurgitation following valve implantation. GlobalData expects this feature to become an industry standard moving forward.

"Additionally, clinical data evaluating safety and efficacy of the Sapien 3 has proved strong so far, with 30-day outcomes from the PARTNER II trial demonstrating a 2.2 percent all-cause mortality rate in inoperable/high-risk patients, compared to the 3.5 percent rate in patients with the Sapien XT."

The analyst added that Medtronic's CoreValve Evolut R updates the original CoreValve design to include a thinner delivery system using a 14F sheath, compared to the original device's 18F sheath. This enables the product to be used in a wider range of artery sizes, expanding the treatment to a greater number of patients.

Unlike the Sapien 3, CoreValve Evolut R is fully repositionable and retrievable, allowing physicians greater control during the fitting procedure. Key opinion leaders have noted the product's easy-to use and intuitive repositionability function, which GlobalData also expects to see in future transcatheter valves.

Meyyan continued: "The approvals of the Sapien 3 and CoreValve Evolut R highlight the increasing adoption and acceptance of TAVR within the medical community as a standard treatment option for valvular heart disease patients.

"Furthermore, they will give Edwards Lifesciences and Medtronic an edge over other TAVR players, such as Boston Scientific and Symetis, which have also been attempting to seize shares in a growing market expected to be worth $3.02 billion by 2020," the analyst concluded.

For more information:

Related Content

Neovasc Files CE Mark for Tiara TA Transapical Mitral Valve Replacement System. TMVR
News | Structural Heart | May 29, 2020
May 29, 2020 — Neovasc Inc., developer of a minimally invasive transcatheter mitral valve replacement (TMVR) technolo
Videos | Structural Heart | April 01, 2020
A review of the PARTNER 3 Low-Risk Trial with ...
Example of an aortic valve CT imaging workup for TAVR valve sizing and assessing access routes. This patient has an aneurysm in the aortic arch. Image from GE Healthcare.

Example of an aortic valve CT imaging workup for TAVR valve sizing and assessing access routes. This patient has an aneurysm in the aortic arch. Image from GE Healthcare.

Feature | Structural Heart | August 12, 2019 | Ashish Pershad, M.D., and Kenith Fang, M.D., FACS
As we usher in a new era for treating patients with aortic stenosis, we have been reflecting on the evolution of the
University of Michigan Partnership Guides New Approach to Acute Aortic Dissection
Feature | Structural Heart | July 18, 2019
When a patient comes to the hospital with acute type A aortic dissection (ATAAD), a tearing of the inner lining of the...
FEops HEARTguide Wins CSI Highlight of the Year Award
News | Structural Heart | July 05, 2019
FEops announced that FEops HEARTguide was the winning entry at CSI Frankfurt 2019 voted on by physician attendees for...